1,1a(2)-(1-Bromo-1,2-ethanediyl)bis[4-fluorobenzene] | 362529-64-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1,1a(2)-(1-Bromo-1,2-ethanediyl)bis[4-fluorobenzene]
• 英文别名: 1-[1-bromo-2-(4-fluorophenyl)ethyl]-4-fluorobenzene
• CAS: 362529-64-4
• 化学式: C₁₄H₁₁BrF₂
• 分子量: 297.14
• InChiKey: BLSQNXDXCFHWRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Azabicyclic heterocycles as cannabinoid receptor modulators
  申请人：Yu Guixue

  公开号：US20050143381A1

  公开（公告）日：2005-06-30

  The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R 1 , R 2 , R 3 , R 6 , R 7 , m and n are described herein.

  本申请描述了符合I式的化合物，包括至少一种符合I式的化合物和可选地一种或多种额外治疗剂的药物组合物，以及使用符合I式的化合物进行治疗的方法，包括单独使用和与一种或多种额外治疗剂结合使用。这些化合物的一般式I如下： 包括所有的前药、药用盐和立体异构体，R1、R2、R3、R6、R7、m和n如本文所述。
• [EN] AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS<br/>[FR] HETEROCYCLES AZABICYCLIQUES EN TANT QUE MODULATEURS DE RECEPTEUR CANNABINOIDE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005063761A1

  公开（公告）日：2005-07-14

  The present application describes compounds according to Formula (I), pharmaceutical compositions comprising at least one compound according to Formula (I) and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula (I) both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula (I) including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.

  本申请描述了按照公式（I）的化合物，包括至少一种按照公式（I）的化合物和可选的一种或多种额外治疗剂量的制药组合物，以及使用按照公式（I）的化合物单独或与一种或多种额外治疗剂量联合使用的治疗方法。化合物的一般公式（I）包括所有前药、药学上可接受的盐和立体异构体，R1、R2、R3、R6、R7、m和n在此被描述。
• Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
  申请人：——

  公开号：US20020091104A1

  公开（公告）日：2002-07-11

  The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. 1 The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.

  本发明包括下式所代表的一类新型化合物，它们是 PTP-1B 酶的抑制剂。 1 本发明还包括治疗或预防 PTP-1B 介导的疾病（包括糖尿病）的药物组合物和方法。
• SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS
  申请人：Merck Frosst Canada & Co.

  公开号：EP1268494A1

  公开（公告）日：2003-01-02
• AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1697370A1

  公开（公告）日：2006-09-06